Apyx Medical Announces Positive Clinical Study for Renuvion in Body Contouring
APYX has more than doubled off its 52-week low of $1.14.
Summary
Apyx Medical announced the publication of a new study showing its Renuvion system significantly improves patient satisfaction and reduces revision rates when used with liposuction.
Key Events · Product Development and Regulatory · APYX
-
Positive Clinical Study Publication
A new retrospective investigator-initiated study was published, evaluating patient-reported outcomes following liposuction with and without Apyx Medical's Renuvion helium plasma radiofrequency.
-
Improved Patient Satisfaction
Patients treated with Renuvion reported statistically higher satisfaction with abdominal appearance and reduced appearance of excess skin compared to conventional liposuction alone.
-
Reduced Revision Rates
The study demonstrated a more than 50% lower rate of abdominoplasty and significantly lower surgical revision rates in the Renuvion group.
-
Comparable Safety Profile
Complication rates remained similar between the Renuvion group and the group receiving power-assisted liposuction only.
Analysis · APYX · Industrial Applications And Services
This publication provides strong clinical validation for Apyx Medical's Renuvion technology, demonstrating improved patient outcomes and reduced need for follow-up procedures in body contouring. The positive data strengthens the product's market position and supports its adoption in a large aesthetic surgery market, reinforcing the company's growth prospects following recent positive financial results and FDA clearance for its AYON system.
At the time of this filing, APYX was trading at $3.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $160.8M. The 52-week trading range was $1.14 to $4.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.